BioCentury
ARTICLE | Distillery Therapeutics

Cancer

October 10, 2017 8:41 PM UTC

Cell culture and mouse studies suggest PRMT5 inhibitors could help treat glioblastoma multiforme (GBM). In human GBM cell lines, shRNA targeting PRMT5 or the PRMT5 inhibitor EPZ015666 decreased proliferation compared with no treatment or vehicle. In xenograft and patient-derived xenograft (PDX) mouse models of GBM, the shRNA targeting PRMT5 or EPZ015666 decreased tumor volume and increased survival. Next steps by Epizyme Inc. and GlaxoSmithKline plc could include testing EPZ015666 in models of other brain cancers...